The recent trend in method of long bone fracture had been toward bracing or closed medullary nailing except for certain fractures that fall within well-established surigcal criteria. Functional bracing is gaining widespread acceptance in management of tibial, femoral, and forearm fractures and is well suited to humeral shaft fractures. Twenty four cases of humeral shaft fractures were treated with functional brace and early mobiliza tion from October 19S2 to June 1984 at Busan National University Hospital and the results were as follows. 1. The fracture sites were composed of middle third in 15 cases, distal third in 6 cases, and proximal third in 3 cases and the fracture shapes were transverse in 10 cases, oblique and spiral in 5 cases respectively, and comminuted in 4 cases. 2. The average time from injury to functional bracing was 13.0 days and to discontinuance of the functional brace was 9.0 weeks. 3. Nonunions have not been encountered in all cases. The residual angulation was under 20degrees in all but one and the most common deformity was varus in 20 cases. Minimum limitation of motion, mostly a loss of the last few degrees of external rotation, was detected after follow-up of 2 months but did not present any clinical problem. 4. The achievement of rapid and uninterrupted osteogenesis without undesirable functional or cos- metic deficit could be listed as the advantage.
Braces ; Busan ; Congenital Abnormalities ; Follow-Up Studies ; Forearm ; Fractures, Bone ; Humerus ; Methods ; Osteogenesis

No abstract available.
Child* ; Chromosome Aberrations* ; Cytogenetic Analysis* ; Cytogenetics* ; Humans

No abstract available.
Immunoglobulin M* ; Lymphoma* ; Paraproteinemias*

Vulva syringomas are rare in reviewing literature. In our case, a 29-year-old had multiple papular lesions involving both sides of the vulva. Microscopically the lesion showed dilated cystic sweat ducts some of which have small comma like tails resembling tadpoles. It is the purpose of this report to present a rare case of syringoma which was limited to the vulva without involvement of other sites.
Adult ; Humans ; Larva ; Sweat ; Syringoma* ; Vulva*

No abstract available.

PURPOSE: We studied the diagnostic significance of bone scan in evaluation of bone metastasis by lung cancer, prevalence rate, and the causes of false positive bone scan and soft tissue accumulation of bone seeking agent. MATERIALS AND METHODS: The subject included 73 lung cancer patients with bone scan. We analyzed the frequency of bone metastasis, its distribution and configuration, and any relationship between bone pain and corresponding region on bone scan. The positive findings of bone scan were compared with simple X-ray film, CT, MRI and other diagnostic modalities. The false positive bone scan and the soft tissue accumulation of bone seeking agent were analized. RESULTS: The positive findings on bone scan were noted in 26 cases(36%) and they were coexistant with bone pain in 30%. The correspondance between bone scan and bone X-ray was 38%. False positive bone scans were seen in 12 cases(16%), which include fracture due to thoracotomy and trauma, degenerative bone diseases, and bifid rib. Accumulation of bone seeking agent in soft tissue were seen in 13 cases(18%), which included primary tumor, enlarged cervical lymph node, pleural effusion, ascites and pleural thickening. CONCLUSION: Bone scans should be carefully interpreted in detecting bone metastasis in primary malignancy, because of the 16% false positivity and 18% soft tissue accumulation rate. It is very important to note that the correlation between bone pain and positive findings of bone scans was only 38%.
Ascites ; Bone Diseases ; Humans ; Lung Neoplasms* ; Lung* ; Lymph Nodes ; Magnetic Resonance Imaging ; Neoplasm Metastasis ; Pleural Effusion ; Prevalence ; Ribs ; Thoracotomy ; X-Ray Film

No abstract available.
Femoral Fractures*

BACKGROUND: CHOP regimen is four-drug, first-generation combination chemotherapy that has been the standard treatment for patients with aggressive non-Hodgkin's lymphoma for the last 20 years. The second- and third-generation regimens have been developed in an attempt to improve the treatment outcome, but recent randomized studies failed to demonstrate an advantage of these regimens compare to the first-generation CHOP regimen. So, we performed clinical study of 8-drug combination chemotherapy, ProMACE-CytaBOM regimen for patients with non-Hodgkin's lymphoma to evaluate the response rate, overall survival, and toxicity. METHODS: Between November 1992 and Feb. 1997, previously untreated stage II/III/IV intermediate- and high-grade non-Hodgkin's lymphoma patients were treated with a ProMACE- CytaBOM regimen including cyclophosphamide 650 mg/m2 IV on day 1, adriamycin 25 mg/m2 IV on day 1, etoposide 120 mg/m2 IV on day 1, cytosine arabinoside 300 mg/m2 IV on day 8, bleomycin 5 mg/m2 IV on day 8, vincristine 1.4 mg/m2 IV on day 8, methotrexate 120 mg/m2 IV on day 8, and prednisone 60 mg/m2 PO on day 1 to day 14 with 3 weeks interval. RESULTS: Twenty eight patients (87.5%) were evaluable. Patient characteristics include: Median age 57.5 years (17-75) and 15 patients were 60 years or old; clinical stage II in 12 patients (37.5%), stage III in 7 patients (21.9%), and stage IV in 13 patients (40.6%). Objective response were 22 CR, 4 PR, 2 PD with 92.8% response rate. The complete response rate was associated with the International Prognostic Index (low risk 100%; low intermediate risk 70%; high and high intermediate risk 50%, P<0.05), but age did not influence the response rate. The median survival time was 23.6 months, and 1-year, 3-year, 5-year total survival and relapse-free survival rate were 75.0% 52.0% 34.7%, 84.4% 84.4% 54.3%, respectively. International Prognostic Index was correlated well with survival time (1-year 3-year 5-year survival : Low risk 91.7% 91.7% 91.7% vs low intermediate risk 80.0% 41.1% 27.4% vs high and high intermediate 33.3% 16.6% 0%, P< 0.005), however age was negatively associated with survival time (1-year 3-year 5-year survival : Below the 60 years 81.3% 75.0% 37.5% vs age greater than 60 years 66.7% 34.3% 22.9%, P<0.05). Grade 3/4 toxicities were anemia in 28.6%, neutropenia in 64.3%, thrombocytopenia in 14.3%, vomiting in 35.7%, oral mucositis in 14.3%, alopecia in 25.0%, increased AST in 3.6% and generation CHOP regimen, with higher treatment-related death due to infection. Therefore, ProMACE-CytaBOM combination chemotherapy is not routinely recommended to treat the patients with non-Hodgkin's lymphoma. CONCLUSION: These data indicate that IDA+BHAC induction chemotherapy seems to be comparable to other combinations for induction chemotherapy in AML. More longer follow-up period is needed for assessing the impact of BHAC-containing regimen on the outcome of autologous and allogeneic hematopoietic stem cell transplantation.
Alopecia ; Anemia ; Bleomycin ; Cyclophosphamide ; Cytarabine ; Doxorubicin ; Drug Therapy, Combination* ; Etoposide ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation ; Humans ; Induction Chemotherapy ; Lymphoma, Non-Hodgkin* ; Methotrexate ; Neutropenia ; Prednisone ; Stomatitis ; Survival Rate ; Thrombocytopenia ; Treatment Outcome ; Vincristine ; Vomiting

BACKGROUND: The eosinophil chemotactic and activating effects of eotaxin and the known association of eosinophils with asthma suggest that eotaxin expression is increased during an asthma attack. This study was aimed to determine whether the plasma eotaxin levels are higher in patients during as asthma attack and to correlate the eotaxin levels with the disease activity, severity and response to therapy. METHOD: A case-control study of the plasma eotaxin levels was performed in 100 patients with exacerbated asthma and 48 age-and sex-matched subjects with stable asthma. RESULTS: The plasma eotaxin levels were significantly higher in the 100 patients with exacerbated asthma (233±175 pg/ml) than in the 48 subjects with stable asthma(169±74 pg/ml). A tread toward higher eotaxin levels was observed in asthmatic subjects who were taking oral steroids (332±225 pg/ml) than in those who were not (214±159 pg/ml) and higher levels were found in those admitted to the hospital (275±212 pg/ml) than in those discharged after receiving only emergency treatment (190±115 pg/ml). The eotaxin levels inversely correlated with the FEV1 (r=-0.25, p<0.01). The eotaxin levels were higher in moderate persistent (323±256 pg/ml) and severe persistent asthmatics (276±170 pg/ml) than in mild intermittent asthmatics (160±60 pg/ml). CONCLUSION: Eotaxin expression is directly associated with asthma exacerbation, impaired pulmonary function and the disease severity.
Asthma* ; Case-Control Studies ; Emergency Treatment ; Eosinophils ; Humans ; Plasma* ; Steroids

Lymphangioleiomyomatosis(LAM) is a rare disease of unknown etiology that occurs mainly in woman in her reproductive age. We recently experienced two cases of bilateral diffuse cystic lesion of the lung on chest X-ray and HRCT. The first case, a 26-year-old female, who had been diagnosed with tuberous sclerosis be the presence of clinical manifestation such as mental retardation, bilateral renal angiomyolipoma, adenoma sebaceum and generalized seizure, was admitted due to recently developed hemoptysis. Chest PA showed diffuse ground-glass opacity with radiolucent cystic lesions of various sizes on both lung fields. HRCT showed innumerable small cystic lesions with suspicious diffuse ground-glass opacity on both lung fields. The second case, a 30-year-old female was admitted due to dyspnea and spewing of blood-tinged sputum for 2 weeks, shortly after delivery. Chest PA showed diffuse reticular and ground-glass opacities on both lung field. HRCT showed multiple well-difined and relatively uniform size air cysts with a uniform wall thickness on entire both lung fields, with small amount of right pleural effusion. By thoracoscopic lung biopsy she was diagnosed with pulmonary lymphangioleiomyomatosis. We report these cases with a brief review of the literatures.
Adult ; Angiomyolipoma ; Biopsy ; Dyspnea ; Female ; Hemoptysis ; Humans ; Intellectual Disability ; Lung ; Lymphangioleiomyomatosis ; Pleural Effusion ; Rare Diseases ; Seizures ; Sputum ; Thorax ; Tuberous Sclerosis